sólo1 - Twitter Search / Twitter
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
First-line Maintenance and Future Directions - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Current status and future prospects of PARP inhibitor clinical trials | CMAR
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer - The ASCO Post
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
Journal of Clinical Oncology al Twitter: "Subgroup efficacy analysis of olaparib maintenance in patients with newly diagnosed ovarian cancer and a BRCA mutation in the SOLO1 trial https://t.co/LE5aobw4It #gyncsm #JCO https://t.co/PtyzfMMMIN" /
Advances in ovarian cancer, from biology to treatment | Nature Cancer
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis | NEJM
The forefront of ovarian cancer therapy: update on PARP inhibitors - Annals of Oncology
IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy | HTML
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect
